ABSTRACT
Cancer or malignant neoplasm refers to a diverse group of diseases where the atypical forms of body’s own cells proliferate uncontrollably and invades neighboring tissues. Radicicol (RD) is the other 1st generation, natural product N-terminal Heat shock protein 90 (Hsp90) inhibitors, which exhibited significant in vitro anticancer activity. The anticancer studies from RD and their derivatives identified a simple scaffold for the future discovery of Hsp90 inhibitors. Hsp90 executes its chaperoning function in association with several co-chaperone proteins. The co-chaperones regulate the chaperoning function by recruiting client protein for Hsp90. Hsp90 plays a major role in the development and progression of cancer. All the aforestated evidences prompted scientists worldwide to rationally design and discover novel anticancer chemical entities that will act via Hsp90 suppression. The drawbacks associated with the first generation Hsp90 antagonists led to the design of derivatives based on the structural features of 1st generation compounds.
